I just want to emphasize that, currently, CAR-T therapies are not particularly effective for solid tumors, which make up the majority of cancer diagnoses. They'

I just want to emphasize that, currently, CAR-T therapies are not particularly effective for solid tumors, which make up the majority of cancer diagnoses. They're currently only good for leukemias and lymphomas. They're also not the first line of treatment, because they have to be genetically engineered from your own cells, and then reinjected into you. There's been some progress in CAR-NK therapies, which would be "off the shelf" in that they don't need to be engineered from your own cells. Also some very preliminary work with allogeneic CAR-T therapies that wouldn't have to be made special for each person.